Pascal Precision News Today

Deal Overview On December 7, 2024, Edwards Lifesciences Corporation (NYSE: EW, $76.90, Market Capitalization: $46.6 billion) in its annual investor call announced its ...

Edwards Lifesciences reported Q3 results that met Wall Street expectations. It remains on track to boost sales by up to 13% this year. 

Edwards Lifesciences (NYSE: EW) shares fell after hours today despite second-quarter results that beat the consensus forecast.

As earnings season is upon us, we're receiving a clearer view of what new medtech could be launching this year in the medical device space.

Edwards Lifesciences (NYSE:EW) announced today that Michael A. Mussallem, chair and CEO, intends to retire next year.

Edwards Lifesciences Corp. is still Orange County’s most valuable publicly traded company, but just barely, after a rough end to October on Wall Street.

Edwards Lifesciences saw persistent U.S. hospital staffing shortages and COVID headwinds in Japan affect its TAVR sales.

Recent developments of interest in cardiovascular medicine

Abbott today announced post-approval study results supporting its MitraClip G4 system for treating mitral regurgitation (MR).

CLASP IID trial crowns no winner but champions expanding choices